It has been previously reported that rolipram could impact on vascular contractility, inducing vascular relaxation in specific vascular beds [40], whereas the consequences of PDE4 inhibition on cardiac function and hypertrophy remains unclear [41,42]. The gene discussed is PDE4A; the disease is hypertrophy.